Osteoarthritis (OA) is the fastest growing cause of disability worldwide, but, with few proven therapeutic options, it is an underserved condition. With increasingly ageing populations contributing to a rising global prevalence, this unmet need only threatens to worsen in the coming years.

At least 60% of females worldwide will experience at least one UTI in their lifetime.4 An array of pathogenic bacteria, both gram-negative and gram-positive, can cause the infections, although in uUTIs, Escherichia coli (E. coli) is the predominant pathogen.

THE 11th European Conference on Rare Diseases (ECRD), partner organisation of the EURORDIS-Rare Diseases Europe, is the largest patient-led rare disease policy event. The fully virtual conference took place from 27th June to 1st July 2022 and saw over 1,000 attendees, including patient advocates, policymakers, researchers, clinicians, healthcare professionals, healthcare industry representatives, academics, payers, regulators, and member state representatives.

Hospitalisation rates for acute bacterial skin and skin structure infection (ABSSSI) are rising and represent a large pharmacoeconomic burden as treatment may involve an extended number of days of antibiotic therapy.

IN THIS year’s European Conference on Rare Diseases & Orphan Products (ECRD), experts, patients, and other stakeholders came together in a session to discuss the best practices for diagnosis and care for people with rare diseases.

Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder with an incidence of 1 in 3,000–5,000.

Kakkar opened the symposium by highlighting the burden of thrombotic disease in patients with cancer with a discussion of data from the Global Anticoagulant Registry in the FIELD – Venous Thromboembolism (GARFIELD-VTE) registry.

Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.

AT the 11th European Conference on Rare Diseases (ECRD), held virtually between 27th June and 1st July as an official event of the 2022 French Presidency of the Council of the European Union (EU), experts discussed how invisibility in rare disease acts as a roadblock to reducing inequalities.

Chronic kidney disease (CKD) is a progressive condition that can lead to kidney failure and the requirement for renal dialysis or transplantation. Early-stage CKD is often missed because the disorder is initially asymptomatic; hence, many patients with CKD already have symptomatic advanced disease (Stages G4–G5) at the time of diagnosis. This is an important issue because the drugs available for the treatment of CKD are most effective when given during the early stages of the disease (Stages G1–G3).